SCHEMBL3364908

SCHEMBL3364908

CCCN(C)CCCCCCOc1ccc(N(C)S(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 2/20 0.48
CACNA1B Q00975 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
PSEN1 P49768 2/20 0.45
PSEN2 P49810 2/20 0.45
APH1B Q8WW43 2/20 0.45
NCSTN Q92542 2/20 0.45
APH1A Q96BI3 2/20 0.45
PSENEN Q9NZ42 2/20 0.45
LSS P48449 4/20 0.45
SERPINE1 P05121 2/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
PTPN1 P18031 1/20 0.41
NR1H3 Q13133 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367913 0.96 CACNA1H (0.48) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3368206 0.93 CACNA1H (0.49) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3364981 0.91 L3MBTL1 (0.48) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3366906 0.91 LSS (0.56) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3366991 0.89 CACNA1B (0.60) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3365715 0.88 LSS (0.54) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3367350 0.88 FFAR1 (0.53) CACNA1HCACNA1BL3MBTL1LSSTDP1
SCHEMBL3365881 0.88 CACNA1B (0.61) CACNA1HCACNA1BL3MBTL1SERPINE1PTPN1
SCHEMBL3363429 0.88 LSS (0.49) CACNA1HCACNA1BL3MBTL1PSEN1PSEN2
SCHEMBL3365014 0.87 LSS (0.53) CACNA1HCACNA1BL3MBTL1LSSSERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303503-B1 ANILINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-01-27 EP disclosed
US-6683201-B2 FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES HOFFMANN-LA ROCHE INC. 2004-01-27 US disclosed
EP-1303503-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020038025-A1 Analine derivatives as OSC inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 US disclosed
WO-2002006189-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038025-A1 Analine derivatives as OSC inhibitors LSS, CYP51A1, CYP46A1 CACNA1H 1926/4885CACNA1B 2736/4885L3MBTL1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.